Literature DB >> 1721627

Interferon-alpha restores the deficient expression of the cytoadhesion molecule lymphocyte function antigen-3 by chronic myelogenous leukemia progenitor cells.

G Upadhyaya1, S C Guba, S A Sih, A P Feinberg, M Talpaz, H M Kantarjian, A B Deisseroth, S G Emerson.   

Abstract

Hematopoietic cells from the malignant clone in chronic myelogenous leukemia (CML) maintain and expand a proliferative advantage over normal hematopoietic cells within the bone marrow. This advantage is often ameliorated or reversed in vivo by IFN alpha. Based upon earlier studies suggesting decreased adhesiveness of CML progenitor cells, we asked whether CML progenitor cells are deficient in their expression of the cytoadhesion molecule lymphocyte function antigen-3 (LFA-3, CD58) which is normally expressed on hematopoietic progenitors. Progenitor cells from untreated CML patients showed greatly reduced or absent LFA-3 expression, whereas progenitors from patients treated with IFN alpha in vivo or in vitro expressed surface LFA-3 at more normal levels. LFA-3-deficient CML progenitor cells were unable to stimulate normal regulatory proliferative responses in autologous T cells. We hypothesize that IFN alpha-sensitive LFA-3 deficiency reflects a cell surface cytoadhesion defect which may help explain adhesive abnormalities of CML progenitor cells in vitro and clonal proliferation in vivo.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1721627      PMCID: PMC295821          DOI: 10.1172/JCI115543

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  24 in total

1.  Bone marrow progenitor cells induce a regulatory autologous proliferative T lymphocyte response.

Authors:  S G Emerson; J H Antin
Journal:  J Immunol       Date:  1989-02-01       Impact factor: 5.422

2.  Enzymatic amplification of beta-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia.

Authors:  R K Saiki; S Scharf; F Faloona; K B Mullis; G T Horn; H A Erlich; N Arnheim
Journal:  Science       Date:  1985-12-20       Impact factor: 47.728

3.  Genetic alterations during colorectal-tumor development.

Authors:  B Vogelstein; E R Fearon; S R Hamilton; S E Kern; A C Preisinger; M Leppert; Y Nakamura; R White; A M Smits; J L Bos
Journal:  N Engl J Med       Date:  1988-09-01       Impact factor: 91.245

4.  Detection of Philadelphia chromosome-positive cells by the polymerase chain reaction following bone marrow transplant for chronic myelogenous leukemia.

Authors:  M S Roth; J H Antin; E L Bingham; D Ginsburg
Journal:  Blood       Date:  1989-08-01       Impact factor: 22.113

Review 5.  Structural and functional roles of glycosyl-phosphatidylinositol in membranes.

Authors:  M G Low; A R Saltiel
Journal:  Science       Date:  1988-01-15       Impact factor: 47.728

6.  Clinical implications of cytogenetic variants in chronic myelocytic leukemia (CML).

Authors:  J Whang-Peng; G P Canellos; P P Carbone; J H Tjio
Journal:  Blood       Date:  1968-11       Impact factor: 22.113

7.  Molecular cloning of the CD2 antigen, the T-cell erythrocyte receptor, by a rapid immunoselection procedure.

Authors:  B Seed; A Aruffo
Journal:  Proc Natl Acad Sci U S A       Date:  1987-05       Impact factor: 11.205

8.  Deficiency of lymphocyte function-associated antigen 3 (LFA-3) in paroxysmal nocturnal hemoglobinuria. Functional correlates and evidence for a phosphatidylinositol membrane anchor.

Authors:  P Selvaraj; M L Dustin; R Silber; M G Low; T A Springer
Journal:  J Exp Med       Date:  1987-10-01       Impact factor: 14.307

9.  Downregulation of cell adhesion molecules LFA-3 and ICAM-1 in Epstein-Barr virus-positive Burkitt's lymphoma underlies tumor cell escape from virus-specific T cell surveillance.

Authors:  C D Gregory; R J Murray; C F Edwards; A B Rickinson
Journal:  J Exp Med       Date:  1988-06-01       Impact factor: 14.307

10.  Primary structure of lymphocyte function-associated antigen 3 (LFA-3). The ligand of the T lymphocyte CD2 glycoprotein.

Authors:  B P Wallner; A Z Frey; R Tizard; R J Mattaliano; C Hession; M E Sanders; M L Dustin; T A Springer
Journal:  J Exp Med       Date:  1987-10-01       Impact factor: 14.307

View more
  10 in total

1.  A randomised clinical trial comparing interferon-alpha and intravenous immunoglobulin in polyneuropathy associated with monoclonal IgM. The IgM-associated Polyneuropathy Study Group.

Authors:  X Mariette; C Chastang; P Clavelou; J P Louboutin; J M Leger; J C Brouet
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-07       Impact factor: 10.154

2.  Interferon-alpha restores normal adhesion of chronic myelogenous leukemia hematopoietic progenitors to bone marrow stroma by correcting impaired beta 1 integrin receptor function.

Authors:  R Bhatia; E A Wayner; P B McGlave; C M Verfaillie
Journal:  J Clin Invest       Date:  1994-07       Impact factor: 14.808

3.  Interaction of the seed and the soil.

Authors:  A B Deisseroth; J Koenig
Journal:  J Clin Invest       Date:  1994-07       Impact factor: 14.808

4.  An in vitro model for cytogenetic conversion in CML. Interferon-alpha preferentially inhibits the outgrowth of malignant stem cells preserved in long-term culture.

Authors:  J J Cornelissen; R E Ploemacher; B W Wognum; A Borsboom; H C Kluin-Nelemans; A Hagemeijer; B Löwenberg
Journal:  J Clin Invest       Date:  1998-09-01       Impact factor: 14.808

5.  Treatment of marrow stroma with interferon-alpha restores normal beta 1 integrin-dependent adhesion of chronic myelogenous leukemia hematopoietic progenitors. Role of MIP-1 alpha.

Authors:  R Bhatia; P B McGlave; C M Verfaillie
Journal:  J Clin Invest       Date:  1995-08       Impact factor: 14.808

Review 6.  Cytokine therapeutics: lessons from interferon alpha.

Authors:  J U Gutterman
Journal:  Proc Natl Acad Sci U S A       Date:  1994-02-15       Impact factor: 11.205

7.  Lytic susceptibility of target cells to cytotoxic T cells is determined by their constitutive major histocompatibility complex class I antigen expression and cytokine-induced activation status.

Authors:  M Ritter; C Huber; J Auböck; H Pohl-Markl; J Troppmair; M Herold; A Gächter; W Nussbaumer; G Böck; D Nachbaur
Journal:  Immunology       Date:  1994-04       Impact factor: 7.397

8.  The human leukemia oncogene bcr-abl abrogates the anchorage requirement but not the growth factor requirement for proliferation.

Authors:  M W Renshaw; J R McWhirter; J Y Wang
Journal:  Mol Cell Biol       Date:  1995-03       Impact factor: 4.272

9.  Upregulated CD58 is associated with clinicopathological characteristics and poor prognosis of patients with pancreatic ductal adenocarcinoma.

Authors:  Yalu Zhang; Qiaofei Liu; Jingkai Liu; Quan Liao
Journal:  Cancer Cell Int       Date:  2021-06-30       Impact factor: 5.722

Review 10.  CD58 Immunobiology at a Glance.

Authors:  Yalu Zhang; Qiaofei Liu; Sen Yang; Quan Liao
Journal:  Front Immunol       Date:  2021-06-08       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.